ABIVAX First-Half 2019 Financial Results and Operations Update - Business Wire

ABIVAX First-Half 2019 Financial Results and Operations Update  Business Wire

Nine-month Phase 2a maintenance study confirmed further clinical improvements, with durability of efficacy and safety of ABX464 in ulcerative colitis patients.



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases